Bristol Myers Squibb ROA 2010-2022 | BMY

Current and historical return on assets (ROA) values for Bristol Myers Squibb (BMY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Bristol Myers Squibb ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $6.62B $100.36B 6.25%
2022-03-31 $6.25B $103.03B 5.76%
2021-12-31 $6.99B $109.31B 6.31%
2021-09-30 $-5.41B $110.89B -4.78%
2021-06-30 $-5.08B $110.80B -4.35%
2021-03-31 $-6.22B $112.44B -5.13%
2020-12-31 $-9.02B $118.48B -7.19%
2020-09-30 $-0.04B $125.54B -0.03%
2020-06-30 $-0.56B $128.08B -0.51%
2020-03-31 $0.95B $129.29B 1.03%
2019-12-31 $3.44B $129.94B 4.96%
2019-09-30 $5.66B $57.43B 12.40%
2019-06-30 $6.20B $55.16B 15.63%
2019-03-31 $5.14B $34.83B 15.11%
2018-12-31 $4.92B $34.99B 14.64%
2018-09-30 $1.43B $33.73B 4.31%
2018-06-30 $0.38B $32.64B 1.13%
2018-03-31 $0.92B $33.08B 2.74%
2017-12-31 $1.01B $33.55B 3.01%
2017-09-30 $4.23B $33.98B 12.62%
2017-06-30 $4.59B $33.41B 13.71%
2017-03-31 $4.84B $32.94B 14.52%
2016-12-31 $4.46B $33.71B 13.49%
2016-09-30 $3.37B $33.73B 10.34%
2016-06-30 $2.87B $32.83B 8.95%
2016-03-31 $1.57B $31.89B 4.94%
2015-12-31 $1.57B $31.75B 4.85%
2015-09-30 $1.78B $31.78B 5.42%
2015-06-30 $1.79B $31.95B 5.39%
2015-03-31 $2.25B $33.58B 6.71%
2014-12-31 $2.00B $33.75B 5.98%
2014-09-30 $2.72B $33.45B 7.82%
2014-06-30 $2.69B $33.50B 7.55%
2014-03-31 $2.89B $33.42B 7.97%
2013-12-31 $2.56B $38.59B 6.95%
2013-09-30 $2.76B $36.80B 7.62%
2013-06-30 $1.36B $36.25B 3.77%
2013-03-31 $1.47B $35.96B 4.20%
2012-12-31 $1.96B $35.90B 5.76%
2012-09-30 $1.89B $36.04B 5.67%
2012-06-30 $3.56B $31.67B 11.04%
2012-03-31 $3.82B $32.41B 11.82%
2011-12-31 $3.70B $32.97B 11.60%
2011-09-30 $3.32B $32.01B 10.56%
2011-06-30 $3.30B $31.83B 10.52%
2011-03-31 $3.33B $30.85B 10.67%
2010-12-31 $3.09B $31.08B 9.91%
2010-09-30 $10.63B $31.89B 34.09%
2010-06-30 $10.64B $31.05B 34.40%
2010-03-31 $10.70B $30.75B 34.93%
2009-12-31 $10.59B $31.01B 34.89%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $160.059B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00